# Nutrient restriction protects against valve interstitial cell calcification by upregulating ubiquitin mediated proteolysis

**Authors:** K. Phadwal, Q. Tang, D. Kurian, X Tan, W. P. Cawthorn, V. E. MacRae

PMC · DOI: 10.3389/fcvm.2025.1586775 · Frontiers in Cardiovascular Medicine · 2025-07-21

## TL;DR

Limiting nutrients can prevent heart valve cell calcification by boosting a cellular cleanup system.

## Contribution

Nutrient restriction is shown to reduce valve cell calcification via upregulating the ubiquitin-proteasome system.

## Key findings

- Nutrient restriction reduced calcium buildup and osteogenic markers in valve cells.
- The ubiquitin-proteasome system was upregulated under nutrient restriction.
- Cul2 and Ube2H are key components in the anti-calcification effects observed.

## Abstract

Calcific aortic valve disease (CAVD) is a common and progressive valvular heart disease characterised by the pathological calcification of valve interstitial cells (VICs). Current clinical treatments, such as surgical valve replacement and transcatheter valve implantation, are invasive and do not target the underlying molecular mechanisms of calcification. Emerging evidence suggests that metabolic interventions may modulate cellular calcification processes. In this study, we investigated the potential of nutrient restriction (NR) as a non-invasive strategy to mitigate VIC calcification, with a particular focus on the role of the ubiquitin-proteasome system (UPS).

Primary rat valvular interstitial cells (RVICs) were cultured and subjected to in vitro calcification using calcium- and phosphate-enriched media. Nutrient restriction was induced by incubating cells in Hank's Balanced Salt Solution (HBSS). Calcification was assessed by quantifying calcium deposition and osteogenic marker expression. To explore the underlying molecular changes, a stable isotope labelling by amino acids in cell culture (SILAC)-based proteomic analysis was performed. The role of the UPS was further examined using pharmacological inhibition with MG132 and siRNA-mediated knockdown of key UPS components, including Cullin-2 (Cul2) and Ubiquitin-conjugating enzyme E2 H (Ube2H).

Nutrient restriction significantly downregulated the expression of osteogenic markers and reduced calcium deposition in RVICs. SILAC-based proteomics revealed the upregulation of multiple components of the UPS in nutrient-restricted cells. Notably, Cul2 and Ube2H were identified as potential key mediators of the anti-calcification effects observed. Inhibition of the proteasome with MG132 exacerbated calcification, while knockdown of Cul2 using siRNA increased osteogenic marker expression and calcium deposition, indicating the essential role of Cul2 in modulating VIC calcification under nutrient-restricted conditions.

This study demonstrates that nutrient restriction effectively attenuates VIC calcification through the modulation of the ubiquitin-proteasome system. The protective role of UPS components, particularly Cul2 and Ube2H, suggests that targeting this pathway could represent a novel therapeutic approach for the management of CAVD. These findings also raise the possibility of employing dietary or metabolic interventions as non-invasive strategies to prevent or delay valve calcification.

## Linked entities

- **Genes:** CUL2 (cullin 2) [NCBI Gene 8453], UBE2H (ubiquitin conjugating enzyme E2 H) [NCBI Gene 7328]
- **Chemicals:** MG132 (PubChem CID 462382)
- **Diseases:** CAVD (MONDO:0010178)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Runx2 (RUNX family transcription factor 2) [NCBI Gene 367218] {aka CBF-alpha-1, Cbfa1, OSF-2}, Adipoq (adiponectin, C1Q and collagen domain containing) [NCBI Gene 246253] {aka Acdc, Acrp30, Adid}, Skp1 (S-phase kinase-associated protein 1) [NCBI Gene 287280] {aka Skp1a}, Eloc (elongin C) [NCBI Gene 64525] {aka Tceb1}, Igfbp1 (insulin-like growth factor binding protein 1) [NCBI Gene 25685] {aka IBP1, IGF-BP25, IGFBA}, Apc (APC regulator of WNT signaling pathway) [NCBI Gene 24205] {aka RATAPC}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, Actb (actin, beta) [NCBI Gene 81822] {aka Actx}, Igf1 (insulin-like growth factor 1) [NCBI Gene 24482] {aka IGF}, Prkaa2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 78975] {aka Ampk, Ampka2}, Sp7 (Sp7 transcription factor) [NCBI Gene 300260] {aka Osx}, Uba7 (ubiquitin-like modifier activating enzyme 7) [NCBI Gene 301000] {aka Ube1l}, HMBS (hydroxymethylbilane synthase) [NCBI Gene 3145] {aka ENCEP, LENCEP, PBG-D, PBGD, PORC, UPS}, Rbx1 (ring-box 1) [NCBI Gene 300084], Gnrhr (gonadotropin releasing hormone receptor) [NCBI Gene 81668] {aka GH1, Lhrhr}, ubiquitin-like [NCBI Gene 108351796], Gcg (glucagon) [NCBI Gene 24952] {aka GLP-1, Glp1, Glp2}, Uba3 (ubiquitin-like modifier activating enzyme 3) [NCBI Gene 117553] {aka Ube1c}, Nedd8 (NEDD8 ubiquitin like modifier) [NCBI Gene 25490] {aka CDK8}, Ube2s (ubiquitin-conjugating enzyme E2S) [NCBI Gene 292588] {aka RGD1564746}, Isg15 (ISG15 ubiquitin-like modifier) [NCBI Gene 298693] {aka G1p2}, Ube2h (ubiquitin-conjugating enzyme E2H) [NCBI Gene 296956], Cul2 (cullin 2) [NCBI Gene 361258], Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Fgf21 (fibroblast growth factor 21) [NCBI Gene 170580] {aka Fgf8c}, Lep (leptin) [NCBI Gene 25608] {aka OB, obese}, Elob (elongin B) [NCBI Gene 81807] {aka Tceb2}, Uba6 (ubiquitin-like modifier activating enzyme 6) [NCBI Gene 305268] {aka RGD1308324, Ube1l2}, Anxa6 (annexin A6) [NCBI Gene 79125] {aka Anx6, CPB-II}, Bglap (bone gamma-carboxyglutamate protein) [NCBI Gene 25295] {aka Bglap2, Bgp, Bgpr, Bgpra}, Ibsp (integrin-binding sialoprotein) [NCBI Gene 24477] {aka Bsp}
- **Diseases:** arterial and valvular calcification (MESH:D061205), Calcification (MESH:D002114), hepatocellular carcinoma (MESH:D006528), valve calcification (MESH:C562942), VICs (MESH:D007984), AS (MESH:D001024), lung adenocarcinoma (MESH:D000077192), cancer (MESH:D009369), HBSS (MESH:D013651), valvular heart disease (MESH:D006349), age (MESH:D019588), CAVD (OMIM:109730), NR (MESH:D002313)
- **Chemicals:** formic acid (MESH:C030544), Arginine (MESH:D001120), o-Cresolphthalein (MESH:C010092), MG132 (MESH:C072553), Lysine (MESH:D008239), rapamycin (MESH:D020123), sorafenib (MESH:D000077157), SDS (MESH:D012967), gentamycin (MESH:D005839), Alamar Blue (MESH:C005843), Pi (MESH:D010716), adrenaline (MESH:D004837), Bis-Tris (MESH:C026272), PVDF (MESH:C024865), phosphate (MESH:D010710), DTT (MESH:D004229), cortisol (MESH:D006854), methionine (MESH:D008715), HCl (MESH:D006851), (6)15N (-), amino acid (MESH:D000596), metformin (MESH:D008687), CO2 (MESH:D002245), ketone bodies (MESH:D007657), ATP (MESH:D000255), Ca (MESH:D002118), glucose (MESH:D005947), acetonitrile (MESH:C032159), cysteine (MESH:D003545), iodoacetamide (MESH:D007460), water (MESH:D014867), Tween-20 (MESH:D011136), trifluoroethanol (MESH:D014270), Peptides (MESH:D010455), resveratrol (MESH:D000077185), Alizarin S (MESH:C010078)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12318972/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12318972/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12318972/full.md

---
Source: https://tomesphere.com/paper/PMC12318972